MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 407969 | Name: STX140
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

STX140 is a bis-sulfamate derivative of the endogenous steroid 2-methoxyestradiol, has shown promising anticancer potency both in vitro and in vivo, with excellent bioavailability. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. STX140 causes apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells.

Chemical Structure

STX140
STX140
CAS#401600-86-0

Theoretical Analysis

MedKoo Cat#: 407969

Name: STX140

CAS#: 401600-86-0

Chemical Formula: C19H28N2O7S2

Exact Mass: 460.1338

Molecular Weight: 460.56

Elemental Analysis: C, 49.55; H, 6.13; N, 6.08; O, 24.32; S, 13.92

Price and Availability

Size Price Availability Quantity
1mg USD 350.00 2 weeks
5mg USD 750.00 2 weeks
10mg USD 1,200.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
STX140; STX-140; STX 140; 2-Methoxyestradiol-3,17-O,O-bis(sulfamate);
IUPAC/Chemical Name
(8R,9S,13S,14S,17S)-2-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diyl bis(sulfamate)
InChi Key
AQSNIXKAKUZPSI-SSTWWWIQSA-N
InChi Code
InChI=1S/C19H28N2O7S2/c1-19-8-7-12-13(15(19)5-6-18(19)28-30(21,24)25)4-3-11-9-17(27-29(20,22)23)16(26-2)10-14(11)12/h9-10,12-13,15,18H,3-8H2,1-2H3,(H2,20,22,23)(H2,21,24,25)/t12-,13+,15-,18-,19-/m0/s1
SMILES Code
C[C@@]12[C@@H](OS(=O)(N)=O)CC[C@@]1([H])[C@]3([H])CCC4=C(C=C(OC)C(OS(=O)(N)=O)=C4)[C@@]3([H])CC2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
STX140 inhibits steroid sulfatase with IC50 values of 39 and 0.5 nM in placental microsomes and MCF-7 cancer cells, respectively. STX140 also binds to carbonic anhydrase IX and II (Kis = 70 and 270 nM, respectively). It inhibits bovine brain tubulin assembly in a cell-free assay (IC50 = 2.2 µM) and tubule formation in HUVECs when used at concentrations of 50 and 100 nM. STX140 inhibits proliferation of LNCaP, PC3, and MDA-MB-231 cancer cells, as well as wild-type A2780 cancer cells and adriamycin- and cisplatin-resistant A2780 cancer cells (IC50s = 530, 400, 618, 330, 870, and 380 nM, respectively).
In vitro activity:
STX140 may hold potential as a therapeutic agent for melanoma treatment. It inhibited cell proliferation in both naïve and resistant melanoma cells, with less impact on melanocytes. STX140 induced cell cycle arrest, reduced migration and clonogenic potential, and inhibited invasion. Additionally, it triggered senescence features in melanoma cells by upregulating senescence-related genes and proteins. Reference: Int J Mol Sci. 2023 Jul 11;24(14):11314. https://pubmed.ncbi.nlm.nih.gov/37511073/
In vivo activity:
STX140 may offer significant benefits to breast cancer patients. In mouse models, STX140 significantly inhibited tumor growth and metastases, with better outcomes than paclitaxel. STX140 also showed a survival advantage and reduced neurotoxicity compared to paclitaxel. Reference: PLoS One. 2013 Dec 6;8(12):e80305. https://pubmed.ncbi.nlm.nih.gov/24324595/
Solvent mg/mL mM
Solubility
DMF 30.0 65.14
DMF:PBS (pH 7.2) (1:7) 0.1 0.22
DMSO 25.0 54.28
Ethanol 14.0 30.40
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 460.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Franco YA, de Moraes MO Jr, Carvalho LAC, Dohle W, da Silva RO, Noma IHY, Lima K, Potter BVL, Machado-Neto JA, Maria-Engler SS. 2-Methoxyestradiol-3,17-O,O-bis-sulfamate (STX140) Inhibits Proliferation and Invasion via Senescence Pathway Induction in Human BRAFi-Resistant Melanoma Cells. Int J Mol Sci. 2023 Jul 11;24(14):11314. doi: 10.3390/ijms241411314. PMID: 37511073; PMCID: PMC10378825. 2. Foster PA, Ho YT, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A. STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells. Anticancer Res. 2009 Oct;29(10):3751-7. PMID: 19846905. 3. Meyer-Losic F, Newman SP, Day JM, Reed MJ, Kasprzyk PG, Purohit A, Foster PA. STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice. PLoS One. 2013 Dec 6;8(12):e80305. doi: 10.1371/journal.pone.0080305. PMID: 24324595; PMCID: PMC3855596. 4. Foster PA, Stengel C, Ali T, Leese MP, Potter BV, Reed MJ, Purohit A, Newman SP. A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anticancer Res. 2008 May-Jun;28(3A):1483-91. PMID: 18630502.
In vitro protocol:
1. Franco YA, de Moraes MO Jr, Carvalho LAC, Dohle W, da Silva RO, Noma IHY, Lima K, Potter BVL, Machado-Neto JA, Maria-Engler SS. 2-Methoxyestradiol-3,17-O,O-bis-sulfamate (STX140) Inhibits Proliferation and Invasion via Senescence Pathway Induction in Human BRAFi-Resistant Melanoma Cells. Int J Mol Sci. 2023 Jul 11;24(14):11314. doi: 10.3390/ijms241411314. PMID: 37511073; PMCID: PMC10378825. 2. Foster PA, Ho YT, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A. STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells. Anticancer Res. 2009 Oct;29(10):3751-7. PMID: 19846905.
In vivo protocol:
1. Meyer-Losic F, Newman SP, Day JM, Reed MJ, Kasprzyk PG, Purohit A, Foster PA. STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice. PLoS One. 2013 Dec 6;8(12):e80305. doi: 10.1371/journal.pone.0080305. PMID: 24324595; PMCID: PMC3855596. 2. Foster PA, Stengel C, Ali T, Leese MP, Potter BV, Reed MJ, Purohit A, Newman SP. A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anticancer Res. 2008 May-Jun;28(3A):1483-91. PMID: 18630502.
1: Andring J, Dohle W, Tu C, Potter BVL, McKenna R. 3,17β-Bis-sulfamoyloxy-2-methoxyestra-1,3,5(10)-triene (STX140) and Non-Steroidal Sulfamate Derivatives Inhibit Carbonic Anhydrase IX: Structure-Activity Optimization for Isoform Selectivity. J Med Chem. 2019 Feb 5. doi: 10.1021/acs.jmedchem.8b01990. [Epub ahead of print] PubMed PMID: 30721041. 2: Stengel C, Newman SP, Leese MP, Thomas MP, Potter BV, Reed MJ, Purohit A, Foster PA. The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression. Anticancer Res. 2015 Oct;35(10):5249-61. PubMed PMID: 26408684; PubMed Central PMCID: PMC4597367. 3: Caira MR, Bourne SA, Samsodien H. Thermal, X-ray Structural, and Dissolution Characteristics of Solid Forms Derived from the Anticancer Agents 2-Methoxyestradiol and 2-Methoxyestradiol-3,17-O,O-Bis-Sulfamate. J Pharm Sci. 2015 Oct;104(10):3418-25. doi: 10.1002/jps.24545. Epub 2015 Jun 12. PubMed PMID: 26073557. 4: Thomas MP, Potter BV. Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health. J Med Chem. 2015 Oct 8;58(19):7634-58. doi: 10.1021/acs.jmedchem.5b00386. Epub 2015 Jun 12. PubMed PMID: 25992880; PubMed Central PMCID: PMC5159624. 5: Meyer-Losic F, Newman SP, Day JM, Reed MJ, Kasprzyk PG, Purohit A, Foster PA. STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice. PLoS One. 2013 Dec 6;8(12):e80305. doi: 10.1371/journal.pone.0080305. eCollection 2013. PubMed PMID: 24324595; PubMed Central PMCID: PMC3855596. 6: Vorster CJ, Joubert AM. In vitro effects of 2-methoxyestradiol-bis-sulphamate on the non-tumorigenic MCF-12A cell line. Cell Biochem Funct. 2010 Jul;28(5):412-9. doi: 10.1002/cbf.1671. PubMed PMID: 20589734. 7: Jourdan F, Leese MP, Dohle W, Hamel E, Ferrandis E, Newman SP, Purohit A, Reed MJ, Potter BV. Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate. J Med Chem. 2010 Apr 8;53(7):2942-51. doi: 10.1021/jm9018806. PubMed PMID: 20225862. 8: Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer. 2010 Jan 19;102(2):316-24. doi: 10.1038/sj.bjc.6605489. Epub 2009 Dec 22. PubMed PMID: 20029418; PubMed Central PMCID: PMC2816659. 9: Foster PA, Ho YT, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A. STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells. Anticancer Res. 2009 Oct;29(10):3751-7. PubMed PMID: 19846905. 10: Day JM, Foster PA, Tutill HJ, Newman SP, Ho YT, Leese MP, Potter BV, Reed MJ, Purohit A. BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure. Br J Cancer. 2009 Feb 10;100(3):476-86. doi: 10.1038/sj.bjc.6604873. Epub 2009 Jan 20. PubMed PMID: 19156141; PubMed Central PMCID: PMC2658539. 11: Tagg SL, Foster PA, Leese MP, Potter BV, Reed MJ, Purohit A, Newman SP. 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer. Br J Cancer. 2008 Dec 2;99(11):1842-8. doi: 10.1038/sj.bjc.6604752. Epub 2008 Nov 4. PubMed PMID: 18985042; PubMed Central PMCID: PMC2600694. 12: Parsons MF, Foster PA, Chander SK, Jhalli R, Newman SP, Leese MP, Potter BV, Purohit A, Reed MJ. The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer. Br J Cancer. 2008 Nov 4;99(9):1433-41. doi: 10.1038/sj.bjc.6604707. Epub 2008 Oct 7. PubMed PMID: 18841154; PubMed Central PMCID: PMC2579677. 13: Foster PA, Stengel C, Ali T, Leese MP, Potter BV, Reed MJ, Purohit A, Newman SP. A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anticancer Res. 2008 May-Jun;28(3A):1483-91. PubMed PMID: 18630502. 14: Foster PA, Newman SP, Leese MP, Bernetiere S, Diolez C, Camara J, Hacher B, Baronnet MM, Ali T, Potter BV, Reed MJ, Purohit A. A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer. Anticancer Res. 2008 Mar-Apr;28(2A):577-81. PubMed PMID: 18506995. 15: Foster PA, Woo LW, Potter BV, Reed MJ, Purohit A. The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology. 2008 Aug;149(8):4035-42. doi: 10.1210/en.2008-0223. Epub 2008 May 1. PubMed PMID: 18450955; PubMed Central PMCID: PMC2488239. 16: Newman SP, Foster PA, Stengel C, Day JM, Ho YT, Judde JG, Lassalle M, Prevost G, Leese MP, Potter BV, Reed MJ, Purohit A. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res. 2008 Jan 15;14(2):597-606. doi: 10.1158/1078-0432.CCR-07-1717. PubMed PMID: 18223236. 17: Newman SP, Foster PA, Ho YT, Day JM, Raobaikady B, Kasprzyk PG, Leese MP, Potter BV, Reed MJ, Purohit A. The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers. Br J Cancer. 2007 Dec 17;97(12):1673-82. Epub 2007 Nov 20. PubMed PMID: 18026194; PubMed Central PMCID: PMC2360283. 18: Foster PA, Ho YT, Newman SP, Kasprzyk PG, Leese MP, Potter BV, Reed MJ, Purohit A. 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res Treat. 2008 Sep;111(2):251-60. Epub 2007 Oct 24. PubMed PMID: 17957467. 19: Newman SP, Ireson CR, Tutill HJ, Day JM, Parsons MF, Leese MP, Potter BV, Reed MJ, Purohit A. The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res. 2006 Jan 1;66(1):324-30. PubMed PMID: 16397246.

View History

Detirelix

Detirelix